Unrelated cord blood transplantation in children with severe congenital neutropenia

YESILIPEK M. A., Tezcan G., GERMESHAUSEN M., Kupesiz A., Uygun V., Hazar V.

PEDIATRIC TRANSPLANTATION, vol.13, no.6, pp.777-781, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 6
  • Publication Date: 2009
  • Doi Number: 10.1111/j.1399-3046.2008.01048.x
  • Journal Name: PEDIATRIC TRANSPLANTATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.777-781
  • Keywords: severe congenital neutropenia, unrelated cord blood transplantation, STEM-CELL TRANSPLANTATION, ACUTE MYELOID-LEUKEMIA, INTENSITY CONDITIONING REGIMEN, STIMULATING-FACTOR-RECEPTOR, MUTATIONS, GENE, EXPERIENCE, PROTEIN, INFANT, DONOR
  • Akdeniz University Affiliated: Yes

Abstract

SCN is an inherited hematological disorder with severe neutropenia and recurrent infections. Although there are some reports that recombinant rhG-CSF improves clinical outcome, allogeneic HSCT appears to be the only curative treatment for these patients. We report here two children with SCN successfully treated by CBT from unrelated donors. They were refractory to rhG-CSF treatment and have no identical family donor. Bu + CY were given as conditioning. Case 1 and Case 2 received 6/6 and 5/6 HLA-matched unrelated umbilical cord blood, respectively. The number of infused nucleated cells was 6, 18 x 10(7)/kg and CD34(+) cell number was 3, 74 x 10(5)/kg in Case 1. Those cell numbers were 8, 8 x 10(7)/kg and 5, 34 x 10(5)/kg for Case 2, respectively. Neutrophil/platelet engraftments were 45/49 days in Case 1 and 24/36 days in Case 2. Grade II cutaneous acute GVHD was seen in Case 2 that was treated successfully with prednisolone. Both patients are well with normal hematological findings and full donor chimerism for post-transplant 20 and 24 months, respectively. We conclude that UCB can be considered as a safe source of stem cell in patients with SCN who need urgent HSCT.